-
ECL Chemiluminescent Substrate Detection Kit Workflow
2026-08-18
Learn how to use the hypersensitive ECL Chemiluminescent Substrate Detection Kit for low-abundance targets on nitrocellulose or PVDF membranes. The workflow combines HRP-based sensitivity, extended signal capture, and practical troubleshooting for reproducible western blot chemiluminescent detection.
-
Canagliflozin for Renal Mitochondrial Research
2026-08-18
Canagliflozin enables researchers to connect renal glucose reabsorption inhibition with proximal-tubule mitochondrial structure and bioenergetics. This workflow-focused guide shows how to design cell and mouse studies, separate glucose-dependent effects from direct cellular readouts, and troubleshoot solvent, sex, and respirometry variables.
-
Mechanical Stress, Cytoskeleton, and Autophagy
2026-08-17
The reference study shows that compression-induced autophagy depends primarily on cytoskeletal microfilaments, while microtubules provide an auxiliary contribution. Its experimental design combines controlled compression, cytoskeletal polymerization perturbation, fluorescence imaging, and western blotting to distinguish structural requirements in mechanotransduction.
-
CTOP: A Causal Tool for μ-Opioid Studies
2026-08-17
CTOP is a selective μ-opioid receptor antagonist for separating receptor-level effects from circuit-level pain phenotypes. This guide translates recent mouse findings on mechanical opioid hypersensitivity into practical assay design, controls, and interpretation.
-
Scalable EPSC-Derived MSC EV Manufacturing
2026-08-16
Gong and colleagues developed a bioreactor-based platform that converts extended pluripotent stem cells into expandable induced mesenchymal stromal cells and therapeutically active extracellular vesicles. The study addresses donor variability and limited manufacturing scale while providing preclinical evidence of comparable activity to primary MSC-derived vesicles in bleomycin-induced pulmonary fibrosis.
-
Novel Allosteric PDK4 Inhibitors for Metabolic Disease
2026-08-15
Lee and colleagues used anthraquinone-based structural optimization to identify compound 8c, a potent allosteric PDK4 inhibitor with activity in biochemical, metabolic, allergic, and cancer-related models. The study supports the lipoamide-binding site as a tractable design region while also showing why pharmacokinetic, mechanistic, and disease-model data must be interpreted together.
-
PXDN, LDHA, and Glycolysis in Glioblastoma
2026-08-14
The reference study integrates transcriptomic network analysis with cellular and in vivo experiments to identify peroxidasin (PXDN) as a glycolysis-associated driver of glioblastoma progression. Its knockdown and LDHA-rescue results support a PXDN–LDHA axis that links metabolic reprogramming with malignant behavior, while also defining important directions for validation in patient-derived models.
-
Cy5 amine (non-sulfonated) Labeling Guide
2026-08-14
Cy5 amine (non-sulfonated) is a primary-amine cyanine reagent for covalent labeling of activated proteins, peptides, polymers, and related biomolecules. Because it is insoluble in water, it must first be dissolved in an organic co-solvent; it is intended for research workflows such as fluorescence microscopy and flow cytometry, not direct aqueous use or diagnostic applications.
-
Measuring Cancer Drug Response Beyond Viability
2026-08-13
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that conventional in vitro drug-response assays can conflate proliferative arrest with cell killing. This framework has practical consequences for interpreting DNA damage response inhibition, cell cycle checkpoint abrogation, and responses to agents such as Wee1 kinase inhibitors.
-
Humanized Gs-DREADD for Neural Circuit Modulation
2026-08-13
Zhang and colleagues developed hM3Ds, a whole-sequence-humanized Gs-coupled DREADD, and showed that it retained a ligand-response profile comparable to the non-human rM3Ds receptor. Selective expression in D1 medium spiny neurons activated the basal ganglia direct pathway and improved Parkinsonian phenotypes in mice, supporting hM3Ds as a useful research tool while leaving clinical safety questions unresolved.
-
Z-VAD-FMK for Apoptosis Assays
2026-08-12
Use Z-VAD-FMK to test whether a treatment-induced phenotype is caspase dependent, rather than merely observing a loss of viability. This workflow connects inhibitor rescue experiments with cell-cycle, apoptotic, and signaling readouts in resistant cancer models.
-
Sulfisomidine: From PK to Assay Design
2026-08-12
Sulfisomidine is a dual-purpose biochemical probe whose antibacterial mechanism and mixed-type hPON1 inhibition can inform better assay design. This article connects historical exposure data with modern enzyme kinetics, microbial metabolism, and environmental study workflows.
-
Paclitaxel (Taxol) Workflows for Cancer Research
2026-08-11
Build reproducible Paclitaxel assays around mitotic arrest, microtubule stabilization, and apoptosis rather than relying on endpoint viability alone. The workflow also shows how Taxol can serve as a chemotherapy stress arm in multi-node PI3K/AKT/mTOR experiments and advanced tumor models.
-
KPT-330: From Nuclear Export to Translation
2026-08-11
KPT-330, also known as Selinexor, offers translational researchers a mechanistically coherent way to study CRM1-dependent nuclear export, tumor suppressor retention, apoptosis, and cell-cycle control. This thought-leadership guide connects oncology evidence with emerging osteoarthritis findings while outlining practical workflows, competitive considerations, and limits on cross-indication interpretation.
-
Z-YVAD-FMK: Reading Caspase-1 in Cell Death
2026-08-10
Discover how Z-YVAD-FMK, a cell-permeable caspase-1 inhibitor, can separate inflammatory caspase signaling from apoptosis and necroptosis. This evidence-led guide translates ricin bystander-cell findings into practical assay and interpretation strategies.